Roflumilast (ARQ-154) Foam 0.3%
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Roflumilast (ARQ-154) Foam 0.3%, covering 2024-03-12 to 2024-03-12. Get the full timeline:
Most recent: Clinical Trial Update: Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM) [Phase 3]